20/20 Biolabs (AIDX) CFO receives 100,000-share stock option grant

Q: How does the 100,000-share AIDX option for Alan Bergman vest?

25,000 shares vest on the first anniversary of the grant date, while the remaining shares vest in equal monthly installments over the following 36 months. All vesting depends on Bergman maintaining continuous service with 20/20 Biolabs during this period.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

20/20 Biolabs, Inc. granted Chief Financial Officer Alan B. Bergman a stock option covering 100,000 shares of common stock. The option has an exercise price of $1.88 per share and expires on April 2, 2036. This is a compensation-related award, not an open-market purchase.

According to the vesting terms, 25,000 shares under the option vest on the first anniversary of the grant date, with the remaining shares vesting in equal monthly installments over the next 36 months, as long as he continues to serve the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bergman Alan B.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	100,000	$0.00	--

Holdings After Transaction: Stock Option — 100,000 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 100,000 shares Exercise price: $1.88 per share Expiration date: April 2, 2036 +3 more

6 metrics

Option grant size 100,000 shares Stock option covering common stock granted to CFO

Exercise price $1.88 per share Stock option exercise price for underlying common stock

Expiration date April 2, 2036 Option term end date

Initial vesting tranche 25,000 shares Vests on first anniversary of grant date

Vesting schedule remainder Equal monthly installments over 36 months After first anniversary, subject to continuous service

Post-transaction derivative holdings 100,000 options Total stock options held after this grant

Key Terms

Stock Option, exercise price, vesting, Common Stock, +1 more

5 terms

Stock Option financial

"security_title: "Stock Option""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price": "1.8800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares subject to the stock option will vest on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"underlying_security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Chief Financial Officer financial

"officer_title": "Chief Financial Officer""

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

Form 4 Insider Transactions: What Each Field Means →

04/06/2026 - 05:56 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bergman Alan B.

(Last)

(First)

(Middle)

C/O 20/20 BIOLABS, INC.,

15810 GAITHER ROAD, SUITE 235

(Street)

GAITHERSBURG

MARYLAND

20877

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
20/20 Biolabs, Inc. [ AIDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option⁽¹⁾	$1.88	04/02/2026		A⁽¹⁾		100,000		⁽¹⁾	04/02/2036	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. 25,000 of the shares subject to the stock option will vest on the first anniversary of the date of grant and the remaining shares will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service to the Issuer.

	s/ Alan B. Bergman	04/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did AIDX executive Alan B. Bergman receive in this Form 4?

Alan B. Bergman received a stock option for 100,000 shares of 20/20 Biolabs common stock as compensation. The award gives him the right to buy these shares later at a fixed price if vesting and service conditions are satisfied.

What is the exercise price and term of Alan Bergman’s AIDX stock option?

The stock option has an exercise price of $1.88 per share and expires on April 2, 2036. This means he can choose to buy up to 100,000 shares at $1.88 any time after vesting and before that expiration date.

Is Alan Bergman buying AIDX shares on the market in this Form 4?

No, this Form 4 reports a compensation-related option grant, not an open-market share purchase. The option was granted at no cost, with a $1.88 exercise price he would pay only if he chooses to exercise in the future.

How many AIDX derivative securities does Alan Bergman hold after this grant?

After the reported transaction, Bergman holds 100,000 stock options for AIDX common shares as shown in the filing. These options reflect a derivative position that may translate into common stock only if vested and exercised before the April 2036 expiration.